Page 16 - 第22屆新創事業獎得獎專輯

科技產業組 Tech Industry Category
CancerFree Biotech Ltd.
President Po-Han, Chen (Po)
Address
3F-2., No. 56, Ln. 258, Ruiguang Rd.,
Tel Neihu Dist., Taipei City, 114 , Taiwan
+886 2 2732 2701
Introduction
CancerFree Biotech was established in 2018.
We are a precision medicine company. Taking
advantage of low-risk and easily accessible
liquid biopsies from blood samples and our
core E.V.A. (Ex Vivo Avatar)Select technology
to culture and expand circulating tumor cells
(CTCs) into CTC-Derived Organoid (CDO), we
can create "Avatars" and provide a platform of
drug sensitivity profiling outside the body of
cancer patients. EVA Select’s personalized
platform for anti-cancer drug screening
can be utilized for numerous solid tumors
and more than 100 cancer medications or
combinations of drugs. Our services enhance
the medication choice process by offering
essential drug-sensitivity information to
patients and healthcare providers.
At CancerFree Biotech, our business philosophy
is firmly rooted in three principles: "Doing
the Right Thing," "Putting Patients First," and
1155
Website https://www.cancerfree.io
Established Dec. 19, 2018
Date
Business EVA Select personalized anti-cancer
Category drug screen
Capital NT$ 21,025,786
"Leading with Exceptional Ideas." CancerFree
Biotech is dedicated to creating a more
extensive, individualized anti-cancer drug testing
service to aid in the recovery of cancer patients.
Product advantages and
competitiveness
The EVA Select platform provides timely ex
vivo amplification of circulating tumor cells
and drug sensitivity screening for cancer
patients. This platform offers clinical feedback
for medical decision-making. The process
is more accessible and less risky than tumor
biopsy. It is a great clinical validation tool for
cancer research. This is also applicable to the
pharmaceutical industry, where it can offer
personalized information that is both real-
time and based on real-world data for clinical
or research applications.